List view / Grid view
Researchers have identified a structural loop in the SARS-CoV-2 S protein and a sequence of four amino acids that they say could help explain its high transmission rate.
After analysing the genomic diversity in SARS-CoV-2 by screening over 7,500 viruses from infected patients, researchers have offered clues for COVID-19 drug development.
Researchers have shown that the activation sequence the SARS-CoV-2 S protein is cleaved by the cellular enzyme furin which is also required for the infection of lung cells.
High-resolution mass spectrometry has been used by researchers to map the glycan-processing states of the Spike protein of the SARS-CoV-2 virus, which causes COVID-19.
Next-generation sequencing has revealed an 81-base pair mutation of the SARS-CoV-2 virus, which could be used to develop new antivirals or vaccines.
A group of researchers has used cryo-EM to discover the structure of the remdesivir-bound RNA complex of SARS-CoV-2 and explain how the drug inhibits COVID-19 viral replication.
A series of three new assays to screen for drug compounds or proteins that combat the COVID-19 coronavirus has been developed.
Bringing together protein science, drug discovery experience and innovative technology, a new collaboration aims to identify novel drug targets for COVID-19.
A new AI tool has been created by researchers to identify the best treatment courses and doses for bacterial or viral infections, such as COVID-19.
Ali Shilatifard’s article explains how investment in institutes performing molecular research is essential, as it is the foundation for all attempts to combat COVID-19 and other future pandemics.
Researchers have found a lead compound which they say inhibits SARS-CoV-2 viral replication and demonstrates good pharmacokinetic activity in vivo.
A new study has revealed that less than 10 percent of respiratory and intestinal cells are susceptible to SARS-CoV-2 infection and expression of ACE2 receptors is driven by the body's immune response.
The developers of a novel method to create immunological assay probes for screening T cells has leveraged their new protocol against COVID-19.
Researchers in the UK have selected nanobodies that bind with high affinity to the Spike protein on the COVID-19 coronavirus, enabling stabilisation for imaging.
The visualisation platform is being used to analyse how the SARS-CoV-2 virus causing COVID-19 is evolving and could be used to inform drug design.
